Student Publications

2024

Li Z, Zhuang X, Pan C-H, Yan Y, Thummalapalli R, Hallin J, Torborg S, Singhal A, Chang JC, Manchado E et al..  2024.  Alveolar Differentiation Drives Resistance to KRAS Inhibition in Lung Adenocarcinoma.. Cancer Discov. 14(2):308-325.
2024
Conti BA, Ruiz PD, Broton C, Blobel NJ, Kottemann MC, Sridhar S, Lach FP, Wiley TF, Sasi NK, Carroll T et al..  2024.  RTF2 controls replication repriming and ribonucleotide excision at the replisome.. Nat Commun. 15(1):1943.
2024
Zhang Z, Schaefer C, Jiang W, Lu Z, Lee J, Sziraki A, Abdulraouf A, Wick B, Haeussler M, Li Z et al..  2024.  A Panoramic View of Cell Population Dynamics in Mammalian Aging.. bioRxiv.
2024
Reichman M, Chen X, Lee A, Losner J, Thomas C, Katzen J.  2024.  Yield of MR-directed US for MRI-detected breast findings: how often can we avoid MR biopsy? Clin Imaging. 111:110174.
2024
Abdulraouf A, Jiang W, Xu Z, Zhang Z, Isakov S, Raihan T, Zhou W, Cao J.  2024.  Optics-free Spatial Genomics for Mapping Mouse Brain Aging.. bioRxiv.
2024
Villasante CM, Deng X, Cohen JE, Hudspeth AJ.  2024.  Nanomechanics of wild-type and mutant dimers of the inner-ear tip-link protein protocadherin 15.. Proc Natl Acad Sci U S A. 121(40):e2404829121.
2024

2023

Mabeza RMark, Christophers B, Ederaine SA, Glenn EJ, Benton-Slocum ZP, Marcelin JR.  2023.  Interventions Associated With Racial and Ethnic Diversity in US Graduate Medical Education: A Scoping Review.. JAMA Netw Open. 6(1):e2249335.
2023
Persad S, Choo Z-N, Dien C, Sohail N, Masilionis I, Chaligne R, Nawy T, Brown CC, Sharma R, Pe'er I et al..  2023.  SEACells infers transcriptional and epigenomic cellular states from single-cell genomics data.. Nat Biotechnol.
2023
Lumaquin-Yin D, Montal E, Johns E, Baggiolini A, Huang T-H, Ma Y, LaPlante C, Suresh S, Studer L, White RM.  2023.  Lipid droplets are a metabolic vulnerability in melanoma.. Nat Commun. 14(1):3192.
2023
Gagne M, Flynn BJ, Honeycutt CCole, Flebbe DR, Andrew SF, Provost SJ, McCormick L, Van Ry A, McCarthy E, Todd J-PM et al..  2023.  RBD-based high affinity ACE2 antagonist limits SARS-CoV-2 replication in upper and lower airways.. bioRxiv.
2023